Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
obesity, BioAge Labs and IPO
BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq
California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a weight loss drug.
Obesity drug developer BioAge Labs aims up to $640 million valuation in upsized US IPO
(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.
Obesity drug developer BioAge raises $198m in IPO
BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%.
IPO, MNTN and Ryan Reynolds
Ryan Reynolds's MNTN Explores Going Public as the IPO Market Shows Signs of Thawing
After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, including Reynolds' MNTN.
Ryan Reynolds’s ad tech firm MNTN looks to Morgan Stanley for 2025 IPO
MNTN, a company that sells targeted TV advertising technology, may be working with Morgan Stanley on an initial public offering (IPO) as the firm considers its future. MNTN has already expanded significantly in recent years acquiring Hollywood star Ryan Reynolds’s agency,
Ryan Reynolds’s MNTN Is Said to Tap Morgan Stanley for 2025 IPO
MNTN, a connected TV advertising platform that counts Hollywood star Ryan Reynolds as its chief creative officer, has picked Morgan Stanley to work on an initial public offering, according to people familiar with the matter.
1d
on MSN
BioAge, BKV shares end their first trading day flat after earlier gains
Obesity-drug developer BioAge jumps nearly 30% while Texas-based Barnett Shale driller BKV posts smaller gain.
FierceBiotech
1d
BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
2h
U.S. IPO Weekly Recap: 3 Sizable Deals Trade Up
Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Read more here.
2d
BioAge seeks nearly $200 million in initial public offering
BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Initial public offering
U.S. Securities and Exchange Commission
BKV
Barnett Shale
Feedback